Sergülen DERVİŞOĞLU, Murat HIZ, Sedat KOCA, Didem Çolpan ÖKSÜZ, Şefika Arzu ERGEN, Elif Eda TİKEN, Nil Molinas MANDEL, Fazilet Öner DİNÇBAŞ

The Role of Radiotherapy in the Treatment of Primary or Recurrent Desmoid Tumors and Long-Term Results

Background: Desmoid tumors are uncommon and benignmesenchymal neoplasms. The optimal treatmentof patients with desmoid tumors is still controversial.Surgery is the primary treatment for locally invasive orrecurrent desmoid tumors. Also, radiotherapy is a treatmentoption for patients at high risk for local failure suchas those with positive margins or recurrent and unresectabletumors.Aims: To report our institutional experience and longtermresults of patients with desmoid tumors who receivedradiotherapy.Study Design: Retrospective cross-sectional study.Methods: Between 1980 and 2009, 20 patients whoreceived radiotherapy (RT) in our institution were analyzed.The majority of patients (80%) were referred witha recurrent tumor after previous surgery. Thirteen patientsunderwent marginal resection, 4 had wide local excisionand 3 patients had only biopsy. Resection marginwas positive in 15 (75%) patients. All patients receivedradiation therapy. The median prescribed dose was 60Gy. Five patients received less than 54 Gy.Results: The median follow-up time was 77.5 months(28-283 months). Nine patients developed local recurrenceafter RT. Seven local failures (78%) were in field.Time to local recurrence ranged from 3-165 months (median33 months). The 2-5 year local control (LC) rateswere 80% and 69%, respectively. On univariate analysis,the 5 year local control rate was significantly better inthe patients treated with ≥54 Gy than in patients who received

PDF

___

1. Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ. Aggressive fibromatozis (desmoids tumor) is a monoclonal disorder. Diag Mol Pathol 1997;6:98-101. [CrossRef]
2. Bonvalot S, Desai A, Coppola C, Le Péchoux C, Terrier P, Dö- mont J, et al. The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol 2012;23 Suppl 10:158-66. [CrossRef]
3. Shinagare AB, Ramaiya NH, Jagannathan JP, Krajewski KM, Giardino AA, Butrynski JE et al. A to Z of Desmoid Tumors. AJR Am J Roentgenol 2011;197:1008-14. [CrossRef]
4. Häyry P, Reitamo JJ, Tötterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol 1982 Jun;77:674-80. [CrossRef]
5. Lewis JJ, Boland PJ, Leung DHY, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann of Surg 1998;229:866-73. [CrossRef]
6. Baumert BG, Spahr MO, Von Hochstetter A, Beauvois S, Landmann C, Fridrich K, et al. The impact of radiotherapy in the treatment of desmoids tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiation Oncology 2007;2:1-12. [CrossRef]
7. Kasper B, Ströbel P, Hohenberger P. Desmoid Tumors: Clinical features and treatment options for advanced disease. The Oncologist 2011;16:682-93. [CrossRef]
8. Rutenberg MS, Indelicato DJ, Knapik JA, Lagmay JP, Morris C, Zlotecki RA, et al. External beam radiotherapy for pediatric and young adult desmoid tumors. Pediatr Blood Cancer 2011;57:435-42. [CrossRef]
9. Nuyttens JJ, Rust PF, Thomas CR, Turrisi AT 3rd. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoids tumors: A comparative review of 22 articles. Cancer 2000;88:1517-23. [CrossRef]
10. Ballo M, Zagars GK, Pollack A, Pisters PWT, Pollock RA. Desmoid Tumor: Prognostic factors and outcome after surgery, radiation therapy or combined surgery and radiation therapy. J Clin Oncol 1999;17:158-67.
11. Shido Y, Nishida Y, Nakashima H, Katagiri H, Sugiura H, Yamada Y. et al. Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Trauma Surg 2009;129:929-33. [CrossRef]
12. Peng PD, Hyder O, Mavros MN, Turley R, Groeschi R, Firoozmand A, et al. Management and recurrence patterns of desmoid tumors: A multi-institutional analysis of 211 patients. Ann Surg Oncol 2012;19:4036-42. [CrossRef]
13. Zlotecki RA, Scarborough MT, Morris CG, Berrey BH, Lind DS, Enneking WF, et al. External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys 2002;54:177-81. [CrossRef]
14. Jelinek JA, Stelzer KJ, Conrad E, Bruckner J, Kliot M, Koh WJ, et al. The efficacy of radiotherapy as postoperative treatment for desmoid tumors. Int J Radiat Oncol Biol Phys 2001;50:121-5. [CrossRef]
15. Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Péchoux CL, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009;16:2587-93. [CrossRef]
16. Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Vince DR, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a waitand-see policy according to tumor presentation. J Clin Oncol 2011;29:3553-8. [CrossRef]
17. Pakos EE. Tsekeris PG, Goussia AC. Desmoid tumours of the extremities and trunk: a review of the literature. Int Orth 2005;29:210-3. [CrossRef]
18. Wood TJ, Quinn KM, Farrokhyar F, Deheshi B, Corbett T, Ghert MA. Local control of extra-abdominal desmoid tumors: systematic review and meta-analysis. Rare Tumors 2013;5:5-10. [CrossRef]
19. Bölükbaşı Y, Kamer S, Anacak Y, Aras A . The Role of Radiotherapy in the Management of Patients with Aggressive Fibromatosis. UHOD 2007; 17: 31-6.
20. Spear M.A., Jennings L.C., Mankin H.J., Spiro I.J., Springfield M.D., Gebhardt M.C., et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 1998;40:637-45. [CrossRef]
21. Melis M, Zager JS, Sondak VK. Multimodality of desmoid tumors: How important is a negative surgical margin ? J of Surg Oncol 2008;98:594-602. [CrossRef]
22. Gluck I, Griffith KA, Bierman JS, Feng FY, Lucas DR, BenJosef E. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 2011;80:787-92. [CrossRef]
23. Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008;34:462-8. [CrossRef]
24. Ozger H, Eralp L, Toker B, Ağaoğlu F, Dizdar Y. Evaluation of prognostic factors affecting recurrences and disease-free survival in extra-abdominal desmoid tumors. Acta Orthop Traumatol Turc 2007;41:291-4.
25. Goy BW, Lee SP, Eilber F, Dorey F, Eckardt J, Fu YS, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys 1997;39:659-65. [CrossRef]
26. McGinn CJ. Chapter:76 Soft tissue sarcomas (excluding retroperitoneum). In: Perez CA, Brady LW, Halperin AC, Schmidt-Ullrich RK., editors. Principles and Practice of Radiation Oncology. Fourt edition, USA: Lippincott Williams & Wilkins, 2004. p.2200.
27. Keus R.B., Nout R.A., Blay J.Y., de Jong J.M., Hennig I., Saran F., et al. Results of a Phase II pilot study of moderate dose radiotherapy for inoperable desmoids-type fibromatosis – an EORTC STBSG and ROG study (EORTC 62991-22998). Annals of Oncology 2013;24:2672-6. [CrossRef]
28. Camargo V.P., Keohan M.L., D’Adamo D.R., Antonescu C.R., Brennan M.F., Singer S., et al. Clinical outcomes of systemic therapy for patients with deep fibromatoses (desmoid tumors). Cancer 2010;116:2258-65.
29. Garbay D., Le Cesne A., Penel N., Chevreau C., Marec-Berard P., Blay J.Y., et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 2012;23:182-6. [CrossRef]
30. Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer 2006;106:208-13. [CrossRef]